| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-10-07 | Horizon Discovery (UK) Servier (France) | kinase inhibitors | Cancer | licensing |
Cancer - Oncology | Licensing agreement |
| 2015-10-07 | Lonza (Switzerland) Benitec BioPharma (Australia) | ddRNAi-based hepatitis C therapy TT-034 | hepatitis C | development manufacturing production |
Infectious diseases | Development agreement |
| 2015-10-07 | Charles River (USA - MA) Antabio (France) | in vitro and in vivo pharmacology, drug metabolism and pharmacokinetics (DMPK), and medicinal chemistry services | services contract |
Infectious diseases - Technology - Services | Services contract | |
| 2015-10-07 | Charles River (USA - MA) Pcovery (Denmark) | in vitro and in vivo pharmacology, drug metabolism and pharmacokinetics (DMPK), and medicinal chemistry services | services contract |
Infectious diseases - Technology - Services | Services contract | |
| 2015-10-07 | Charles River (USA - MA) the British Columbia Cancer Agency (Canada) | chemistry/computer-aided drug design (CADD), biochemical and cell assays, and in vitro and in vivo DMPK studies to improve radiotherapy treatments for cancer | services contract |
Cancer - Oncology - Technology - Services | Services contract | |
| 2015-10-07 | CEVEC Pharmaceuticals (Germany) CellGenix (Germany) | selected cytokines for ex vivo cell culture therapy applications | development licensing |
Technology - Services | Licensing agreement | |
| 2015-10-06 | The Medicines Company (USA - NJ) SymBio Pharmaceuticals (Japan) | Ionsys® (fentanyl iontophoretic transdermal system) | post-operative pain in adult patients requiring opioid analgesia in the hospital | licensing development commercialisation |
CNS diseases | Licensing agreement |
| 2015-10-06 | Adaptimmune (UK) | new facility at Milton Park | construction of new premises |
Cancer - Oncology | Construction of new premises | |
| 2015-10-06 | Abeona Therapeutics (USA - NY) Stanford University (USA - CA) | AAV (adeno-associated virus) delivery vector | Fanconi anemia | licensing |
Rare diseases - Genetic diseases - Hematological diseases | Licensing agreement |
| 2015-10-05 | Evotec (Germany) National Cancer Institute (USA) | Technology - Services | Services contract | |||
| 2015-10-05 | Crossbeta Biosciences (The Netherlands) Servier (France) | oligomers | R&D |
Neurological diseases - CNS diseases | R&D agreement | |
| 2015-10-05 | Arena Pharmaceuticals (USA - CA) | resignation |
Resignation | |||
| 2015-10-05 | Epigenomics (Germany - USA) | nomination |
Cancer - Oncology - Rare diseases | Nomination | ||
| 2015-10-02 | Vernalis (UK) Pragma Pharmaceuticals (USA - NY) | Moxatag® (amoxicillin extended release tablets) | tonsillitis and/or pharyngitis secondary to streptococcus pyogenes in adults and paediatric patients 12 years of age or older. | product acquisition |
Infectious diseases | Product acquisition |
| 2015-10-02 | Allergan (Ireland) Humana (USA - KY) | health services | collaboration |
Collaboration agreement | ||
| 2015-10-01 | Merck KGaA (Germany) Biomarin Pharmaceutical (USA - CA) | Kuvan®, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase or ‘PAL’, pegvaliase) | phenylketonuria | licensing development commercialisation |
Rare diseases - Genetic diseases - Metabolic diseases | Licensing agreement |
| 2015-10-01 | Pfizer (USA - NY) GSK (UK) | Nimenrix®, Mencevax® | prevention of meningococcal disease | product acquisition |
Infectious diseases | Product acquisition |
| 2015-10-01 | Sarepta Therapeutics (USA - MA) Murdoch University (Australia) | multiple sclerosis, cystic fibrosis, spinal muscular atrophy | R&D |
Neurodegenerative diseases - Rare diseases - Genetic diseases - Neuromuscular diseases | R&D agreement | |
| 2015-10-01 | Novartis (Switzerland) Xoma (USA - CA) | anti-transforming growth factor-beta (TGFb) antibody program including XOMA 089 | licensing development commercialisation |
Cancer - Oncology | Licensing agreement | |
| 2015-10-01 | Regeneron Pharmaceuticals (USA - NY) Mitsubishi Tanabe Pharma (Japan) | fasinumab (REGN475) | musculoskeletal pain | development commercialisation |
CNS diseases - Muscular diseases | Development agreement |
